New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. New research shows that a needle-free mucosal bacteriophage ...
Venigalla B. Rao, PhD, has been studying bacteriophages for more than four decades, mostly in small laboratories with limited personnel and funding. But having a mere eight-person lab (four post-docs, ...
In a recent study published in the journal Nature Communications, researchers present a method for constructing artificial viral vectors (AVVs) using the established structural components of ...
Aims: Novel anticancer strategies have employed bacteriophages as drug carriers and display platforms for anticancer agents; however, bacteriophage-based platforms maintain their natural antibacterial ...
Atomic structural model of bacteriophage T4 in UCSF Chimera software using pdbs of the individual proteins. Credit: Dr. Victor Padilla-Sanchez, PhD, CC BY-SA 4.0 Atomic structural model of ...
In a recent study posted to bioRxiv* preprint server, researchers developed a mucosal vaccine for coronavirus disease 2019 (COVID-19) based on bacteriophage. Vaccines against severe acute respiratory ...
A cryo-EM depiction of jumbo phage compared with a T4 phage virus and a ribosome particle. Villa Lab, UC San Diego Must be used in conjunction with Nature paper on jumbo phage-infected bacterial cells ...
BioVenic offers one-stop solutions for veterinary vaccine development for protecting animals against various pathogen type.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results